drugset / Trial / NCT00654901
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a follow-up of Study A3L11 (NCT00404651). Immunogenicity * To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-Hep B-PRP\~T or Infanrix hexa™. * To describe the immunogenicity of a booster dose of DTaP-IPV-HepB-PRP\~T in a subset of subjects. Safety \- To describe the safety profile after a booster dose of DTacP-IPV-HepB-PRP\~T.
Timeline
- Start
- 2008-03
- Primary completion
- 2009-05
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Infanrix hexa | Vaccine | 0.5 ml | Intramuscular |
| Subject | Prevnar 13 | Vaccine | 0.5 ml | Intramuscular |